MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1 (vol 35, pg 6189, 2016)-MedSci.cn - williamhill asia

MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1 (vol 35, pg 6189, 2016)

Venturutti, L; Russo, RIC; Rivas, MA; Mercogliano, MF; Izzo, F; Oakley, RH; Pereyra, MG; De Martino, M; Proietti, CJ; Yankilevich, P; Roa, JC; Guzman, P; Cortese, E; Allemand, DH; Huang, TH; Charreau, EH; Cidlowski, JA; Schillaci, R; Elizalde, PV

ONCOGENE, 2023; ():

科室
- - 订阅+
  - 更多科室
工具
服务